120 related articles for article (PubMed ID: 23984895)
1. Rational cotargeting of Pim-1 and Akt in prostate cancer.
Toren P; Zoubeidi A
Expert Rev Anticancer Ther; 2013 Aug; 13(8):937-9. PubMed ID: 23984895
[TBL] [Abstract][Full Text] [Related]
2. Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1.
Cen B; Mahajan S; Wang W; Kraft AS
Cancer Res; 2013 Jun; 73(11):3402-11. PubMed ID: 23585456
[TBL] [Abstract][Full Text] [Related]
3. PIM activity in tumours: A key node of therapy resistance.
Rebello RJ; Huglo AV; Furic L
Adv Biol Regul; 2018 Jan; 67():163-169. PubMed ID: 29111105
[TBL] [Abstract][Full Text] [Related]
4. PIM Kinases and Their Relevance to the PI3K/AKT/mTOR Pathway in the Regulation of Ovarian Cancer.
Aziz AUR; Farid S; Qin K; Wang H; Liu B
Biomolecules; 2018 Feb; 8(1):. PubMed ID: 29401696
[TBL] [Abstract][Full Text] [Related]
5. eIF4B is a convergent target and critical effector of oncogenic Pim and PI3K/Akt/mTOR signaling pathways in Abl transformants.
Chen K; Yang J; Li J; Wang X; Chen Y; Huang S; Chen JL
Oncotarget; 2016 Mar; 7(9):10073-89. PubMed ID: 26848623
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms Behind Resistance to PI3K Inhibitor Treatment Induced by the PIM Kinase.
Song JH; Singh N; Luevano LA; Padi SKR; Okumura K; Olive V; Black SM; Warfel NA; Goodrich DW; Kraft AS
Mol Cancer Ther; 2018 Dec; 17(12):2710-2721. PubMed ID: 30190422
[TBL] [Abstract][Full Text] [Related]
7. Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma.
Schatz JH; Oricchio E; Wolfe AL; Jiang M; Linkov I; Maragulia J; Shi W; Zhang Z; Rajasekhar VK; Pagano NC; Porco JA; Teruya-Feldstein J; Rosen N; Zelenetz AD; Pelletier J; Wendel HG
J Exp Med; 2011 Aug; 208(9):1799-807. PubMed ID: 21859846
[TBL] [Abstract][Full Text] [Related]
8. PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancer.
Goc A; Al-Husein B; Kochuparambil ST; Liu J; Heston WW; Somanath PR
Int J Oncol; 2011 Jan; 38(1):267-77. PubMed ID: 21109949
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Pim kinases triggers a broad antiviral activity by affecting innate immunity and via the PI3K-Akt-mTOR axis the endolysosomal system.
Glitscher M; Benz NI; Sabino C; Murra RO; Hein S; Zahn T; Mhedhbi I; Stefanova D; Bender D; Werner S; Hildt E
Antiviral Res; 2024 Jun; 226():105891. PubMed ID: 38649071
[TBL] [Abstract][Full Text] [Related]
10. PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer.
Luszczak S; Kumar C; Sathyadevan VK; Simpson BS; Gately KA; Whitaker HC; Heavey S
Signal Transduct Target Ther; 2020 Jan; 5(1):7. PubMed ID: 32296034
[TBL] [Abstract][Full Text] [Related]
11. PIM kinase (and Akt) biology and signaling in tumors.
Warfel NA; Kraft AS
Pharmacol Ther; 2015 Jul; 151():41-9. PubMed ID: 25749412
[TBL] [Abstract][Full Text] [Related]
12. The survival kinases Akt and Pim as potential pharmacological targets.
Amaravadi R; Thompson CB
J Clin Invest; 2005 Oct; 115(10):2618-24. PubMed ID: 16200194
[TBL] [Abstract][Full Text] [Related]
13. Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities (review).
Toren P; Zoubeidi A
Int J Oncol; 2014 Nov; 45(5):1793-801. PubMed ID: 25120209
[TBL] [Abstract][Full Text] [Related]
14. The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.
Rebello RJ; Kusnadi E; Cameron DP; Pearson HB; Lesmana A; Devlin JR; Drygin D; Clark AK; Porter L; Pedersen J; Sandhu S; Risbridger GP; Pearson RB; Hannan RD; Furic L
Clin Cancer Res; 2016 Nov; 22(22):5539-5552. PubMed ID: 27486174
[TBL] [Abstract][Full Text] [Related]
15. Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance.
Chang L; Graham PH; Ni J; Hao J; Bucci J; Cozzi PJ; Li Y
Crit Rev Oncol Hematol; 2015 Dec; 96(3):507-17. PubMed ID: 26253360
[TBL] [Abstract][Full Text] [Related]
16. Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
Liu L; Dong X
PLoS One; 2014; 9(10):e108780. PubMed ID: 25360799
[TBL] [Abstract][Full Text] [Related]
17. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.
Kirschner AN; Wang J; van der Meer R; Anderson PD; Franco-Coronel OE; Kushner MH; Everett JH; Hameed O; Keeton EK; Ahdesmaki M; Grosskurth SE; Huszar D; Abdulkadir SA
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25505253
[TBL] [Abstract][Full Text] [Related]
18. Mechanism-based combinations with Pim kinase inhibitors in cancer treatments.
Yang Q; Chen LS; Gandhi V
Curr Pharm Des; 2014; 20(42):6670-81. PubMed ID: 25341939
[TBL] [Abstract][Full Text] [Related]
19. Pim Kinases Promote Migration and Metastatic Growth of Prostate Cancer Xenografts.
Santio NM; Eerola SK; Paatero I; Yli-Kauhaluoma J; Anizon F; Moreau P; Tuomela J; Härkönen P; Koskinen PJ
PLoS One; 2015; 10(6):e0130340. PubMed ID: 26075720
[TBL] [Abstract][Full Text] [Related]
20. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]